Acclaimed melanoma expert and former Australian of the Year Professor Richard Scolyer has shared a heartbreaking update on his battle with brain cancer – revealing the disease is advancing again.

The prevalence and severity of rheumatic adverse reactions in cancer immunotherapy is significantly underestimated, due to ...

Fortune Feimster revealed that her mother Ginger was diagnosed with Intrahepatic Cholangiocarcinoma, a rare and aggressive ...

Instead, Sideris found her way into a clinical trial, testing an immunotherapy drug for people with a rare cancer type. After ...

Teddi Mellencamp gave an update on her health, including her tumors and her body's response to immunotherapy, during the ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Our study investigated the role of astrocytes, an abundant cell type in the brain, in regulating an immune response against ...

A promising new study is changing the way doctors think about treating certain cancers. The research focuses on immunotherapy ...

The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising ...

A common class of antidepressant medications might be even more useful than we thought. Research out today suggests that ...

Explore the transformative impact and development of T-Cell Immunotherapies in pharmaceuticals. Gain expert insights into trends, sales forecasts, company pipelines, and future priorities. Essential ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...